Skip to main content

Sleeve Gastrectomy with Adjunct Intestinal Bypass ("Sleeve Plus") Procedures Versus Sleeve Gastrectomy Alone: A Systematic Review and Meta-Analysis

In brief

Two sleeve-plus procedures linked to greater weight loss and diabetes remission

A review of 37 studies involving 4,692 patients found that SADI-S and SASI, two sleeve-plus procedures, were associated with greater weight loss and type 2 diabetes remission than sleeve surgery alone. Safety differences were uncertain, and the evidence was mostly observational, heterogeneous, and based on a median 12 months of follow-up, so longer randomized trials are needed.

Journal
Obesity surgery (Q1)
Published
16 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Ralph Victor Yap, Nicha Srisuworanan, Yosuke Seki, Kazunori Kasama
PMID
43037950
DOI
10.1007/s11695-026-09022-4

Why clinicians should know about it

  • Picked for Bariatric and Metabolic Surgery (paper of the day, 18 November 2026): Compares sleeve gastrectomy variants, weight loss, remission, and complications

Abstract

Sleeve gastrectomy (SG) has limitations, prompting the development of adjunctive "Sleeve Plus" procedures. This meta-analysis compared outcomes of SG Plus procedures versus SG alone. Thirty-seven studies (4 RCTs, 33 observational) with 4,692 patients were included. Procedure-specific analyses revealed that SADI-S and SASI were associated with significantly greater weight loss and T2DM remission versus SG. No statistically significant differences in major complications were detected; however, the estimates were imprecise and did not exclude a clinically important increase in risk. SG-JJB demonstrated modest weight loss benefits, while comparative safety estimates were limited by sparse events and imprecision. SG-DJB showed modestly higher major complication rates without significant efficacy benefits. Given the predominance of observational data, substantial heterogeneity, short follow-up (median 12 months), and predominantly low-to-very-low certainty of evidence, these findings are exploratory and hypothesis-generating. Comparative safety and efficacy profiles vary across individual SG Plus techniques, supporting procedure-specific shared decision-making and underscoring the need for long-term randomized controlled trials. PROSPERO registration: CRD420251161779.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.